221 related articles for article (PubMed ID: 10626361)
1. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches.
Screnci D; McKeage MJ
J Inorg Biochem; 1999 Oct; 77(1-2):105-10. PubMed ID: 10626361
[TBL] [Abstract][Full Text] [Related]
2. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity.
Carozzi VA; Marmiroli P; Cavaletti G
Curr Cancer Drug Targets; 2010 Nov; 10(7):670-82. PubMed ID: 20578989
[TBL] [Abstract][Full Text] [Related]
3. Platinum-induced neurotoxicity and preventive strategies: past, present, and future.
Avan A; Postma TJ; Ceresa C; Avan A; Cavaletti G; Giovannetti E; Peters GJ
Oncologist; 2015 Apr; 20(4):411-32. PubMed ID: 25765877
[TBL] [Abstract][Full Text] [Related]
4. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
5. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.
Liu JJ; Kim Y; Yan F; Ding Q; Ip V; Jong NN; Mercer JF; McKeage MJ
Biochem Pharmacol; 2013 Jan; 85(2):207-15. PubMed ID: 23123662
[TBL] [Abstract][Full Text] [Related]
6. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
McKeage MJ; Hsu T; Screnci D; Haddad G; Baguley BC
Br J Cancer; 2001 Oct; 85(8):1219-25. PubMed ID: 11710838
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.
Ali BH
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):272-9. PubMed ID: 20050845
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
10. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
11. Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy?
Di Cesare Mannelli L; Pacini A; Micheli L; Femia AP; Maresca M; Zanardelli M; Vannacci A; Gallo E; Bilia AR; Caderni G; Firenzuoli F; Mugelli A; Ghelardini C
Sci Rep; 2017 Feb; 7():42021. PubMed ID: 28186109
[TBL] [Abstract][Full Text] [Related]
12. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
Screnci D; McKeage MJ; Galettis P; Hambley TW; Palmer BD; Baguley BC
Br J Cancer; 2000 Feb; 82(4):966-72. PubMed ID: 10732773
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.
Ta LE; Espeset L; Podratz J; Windebank AJ
Neurotoxicology; 2006 Dec; 27(6):992-1002. PubMed ID: 16797073
[TBL] [Abstract][Full Text] [Related]
15. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.
Liu JJ; Jamieson SM; Subramaniam J; Ip V; Jong NN; Mercer JF; McKeage MJ
Cancer Chemother Pharmacol; 2009 Sep; 64(4):847-56. PubMed ID: 19466412
[TBL] [Abstract][Full Text] [Related]
16. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
Holmes J; Stanko J; Varchenko M; Ding H; Madden VJ; Bagnell CR; Wyrick SD; Chaney SG
Toxicol Sci; 1998 Dec; 46(2):342-51. PubMed ID: 10048138
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research.
Vekris A; Meynard D; Haaz MC; Bayssas M; Bonnet J; Robert J
Cancer Res; 2004 Jan; 64(1):356-62. PubMed ID: 14729645
[TBL] [Abstract][Full Text] [Related]
18. Use of C. elegans as a 3R-compliant in vivo model for the chemoprevention of cisplatin-induced neurotoxicity.
Wellenberg A; Weides L; Kurzke J; Hennecke T; Bornhorst J; Crone B; Karst U; Brinkmann V; Fritz G; Honnen S
Exp Neurol; 2021 Jul; 341():113705. PubMed ID: 33753139
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.
Jamieson SM; Subramaniam J; Liu JJ; Jong NN; Ip V; Connor B; McKeage MJ
Mol Pain; 2009 Nov; 5():66. PubMed ID: 19922644
[TBL] [Abstract][Full Text] [Related]
20. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity.
Cavaletti G; Ceresa C; Nicolini G; Marmiroli P
Anticancer Res; 2014 Jan; 34(1):483-6. PubMed ID: 24403505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
